In December, the U.S. Food and Drug Administration (FDA) approved nivolumab and hyaluronidase-nvhv (Opdivo Qvantig) for subcutaneous injection across all of nivolumab’s approved adult solid tumor indications, including melanoma.
Of Interest
Report Highlights Role of Cancer-Associated Fibroblasts in Melanoma Metastases
The study could open the door to potential novel therapeutic targets.
New immunotherapy strategy targets macrophage receptors to enhance melanoma treatment
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study, published in the Journal for ImmunoTherapy of Cancer, shows that blocking MARCO in combination with a type of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor regression in melanoma, the deadliest form of skin cancer.
Remote Telemedicine Tool Highly Accurate in Diagnosing Melanoma
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying melanomas as having a dermatologist examine them in person, a new study showed.